1. Home
  2. BCLI vs GRF Comparison

BCLI vs GRF Comparison

Compare BCLI & GRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCLI
  • GRF
  • Stock Information
  • Founded
  • BCLI 2000
  • GRF 1989
  • Country
  • BCLI United States
  • GRF United States
  • Employees
  • BCLI N/A
  • GRF N/A
  • Industry
  • BCLI Biotechnology: Biological Products (No Diagnostic Substances)
  • GRF Finance/Investors Services
  • Sector
  • BCLI Health Care
  • GRF Finance
  • Exchange
  • BCLI Nasdaq
  • GRF Nasdaq
  • Market Cap
  • BCLI 37.7M
  • GRF 36.7M
  • IPO Year
  • BCLI N/A
  • GRF N/A
  • Fundamental
  • Price
  • BCLI $0.40
  • GRF $9.44
  • Analyst Decision
  • BCLI Strong Buy
  • GRF
  • Analyst Count
  • BCLI 1
  • GRF 0
  • Target Price
  • BCLI $2.00
  • GRF N/A
  • AVG Volume (30 Days)
  • BCLI 824.4K
  • GRF 3.0K
  • Earning Date
  • BCLI 08-12-2024
  • GRF 01-01-0001
  • Dividend Yield
  • BCLI N/A
  • GRF 3.70%
  • EPS Growth
  • BCLI N/A
  • GRF N/A
  • EPS
  • BCLI N/A
  • GRF 1.16
  • Revenue
  • BCLI N/A
  • GRF N/A
  • Revenue This Year
  • BCLI N/A
  • GRF N/A
  • Revenue Next Year
  • BCLI N/A
  • GRF N/A
  • P/E Ratio
  • BCLI N/A
  • GRF $8.15
  • Revenue Growth
  • BCLI N/A
  • GRF N/A
  • 52 Week Low
  • BCLI $0.13
  • GRF $7.93
  • 52 Week High
  • BCLI $1.93
  • GRF $10.19
  • Technical
  • Relative Strength Index (RSI)
  • BCLI 52.15
  • GRF 58.19
  • Support Level
  • BCLI $0.33
  • GRF $9.32
  • Resistance Level
  • BCLI $0.38
  • GRF $9.55
  • Average True Range (ATR)
  • BCLI 0.03
  • GRF 0.09
  • MACD
  • BCLI 0.01
  • GRF 0.01
  • Stochastic Oscillator
  • BCLI 83.30
  • GRF 80.43

About BCLI Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

About GRF Eagle Capital Growth Fund Inc.

Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments.

Share on Social Networks: